BayWa's Restructuring Strategy Faces Major Setback

Expiration of U.S. green subsidies slashes value of BayWa's renewable energy unit, forcing renegotiation with creditors and delaying key financial reports.

A significant shift in U.S. legislation has delivered a severe blow to the ongoing restructuring efforts of German agricultural conglomerate BayWa. The company's recovery timeline has been thrown into disarray, forcing management back to the negotiating table with creditors, after the valuation of its most important subsidiary collapsed.

Legislative Change Undermines Core Asset Value

The root of the new crisis lies in the expiration of U.S. subsidies for wind and solar projects under the "One Big Beautiful Bill Act." This regulatory reversal strikes directly at the heart of BayWa's subsidiary, BayWa r.e. AG. A planned partial sale of this renewable energy division had been considered a cornerstone of the strategy to rescue the heavily indebted parent company.

Previously, management aimed to generate approximately €1.7 billion from selling a 51% stake by 2028. That plan is now obsolete under the new regulatory framework. The profit forecast for the energy division has undergone a drastic correction. The company now projects an EBITDA of just €150 million for 2030, a sharp decline from the €230 million it had anticipated for 2028.

Financial Timelines Extended, Bank Support Crucial

The mandatory revision of long-term business planning carries profound consequences for financial reporting obligations. The audited group financial statements for the 2025 fiscal year will face a substantial delay. Munich-based executives now expect the certified figures in the fourth quarter, rather than in April 2026 as originally scheduled.

Concurrently, the board is engaged in intensive discussions with financing partners and major shareholders regarding an extension of existing deadlines. A comprehensive standstill agreement until autumn 2026 is intended to secure ongoing operations in the core agriculture and building materials segments. Investors on the stock exchange are greeting this uncertainty with persistent skepticism. Shares closed at €14.25 on Thursday, accumulating a 29.46% loss over the preceding twelve-month period.

In an effort to partially bridge the resulting valuation gap, the group has already begun divesting non-core activities. The completed sale of its Dutch subsidiary Cefetra in February yielded gross proceeds of €125 million. This sum alone, however, is insufficient to ensure the successful conclusion of the transformation scheduled through 2028. The company's operational viability now depends entirely on the willingness of its banks to support the adjusted recovery plan, despite the severely damaged U.S. forecasts.